Sign inJoin waitlistJoin the waitlist

Ehab Atallah

Associate Director, Cancer Service Line · Medical College of Wisconsin Affiliated Hospitals, Inc

Credentials: · · · ·

History

Medical College of Wisconsin Affiliated Hospitals, Inc
Present

University of Texas M D Anderson Cancer Center
2006–2007
Hematology and Medical Oncology
Wayne State University
2003–2006
Cleveland Clinic Foundation
2001–2003
Doctor of Medicine - Kasr Al-Ainy Medical School - Cairo
1990–1994

Research

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
New England Journal of Medicine · 2024 · 235 citations
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia:…
Journal of Clinical Oncology · 2017 · 219 citations
Congestive heart failure is a rare event in patients receiving imatinib therapy
Blood · 2007 · First of 4 authors · 179 citations

Mark Litzow
24 papers
Talha Badar
21 papers · 2 as a fellow
Laura Michaelis
16 papers
RS
Rory Shallis
16 papers
Vamsi Kota
16 papers
Anand Patel
15 papers · 3 as a fellow
Guru Murthy
14 papers · 5 as a fellow
Jorge Cortes
13 papers
Sameem Abedin
12 papers · 1 as a fellow
Hagop Kantarjian
11 papers
AD
Adam DuVall
10 papers
MM
Michael Mauro
10 papers

Grants

Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
National Cancer Institute · R01
Contact PI · $3.3M · Medical College of Wisconsin
2014–2021

Clinical trials

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Principal investigator · Terminated · Phase 1
Ehab L Atallah
2022–2024
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Principal investigator · Recruiting · Phase 2
Medical College of Wisconsin
2021–2029
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
Principal investigator · Terminated · Phase 1
Medical College of Wisconsin
2020–2022
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Principal investigator · Withdrawn · Phase 1
Ehab L Atallah
2017–2018